Praxis Precision Medicines Announces Third Quarter 2026 Financial Results Date, Investor Day and November Conference Participation
Globe Newswire•27/10/2026•16:01 ET
0
Key Highlights
- ➤Q3 2026 financial results scheduled for November 9 before market open
- ➤Investor Day set for November 12 in New York
- ➤Ulixacaltamide and relutrigine remain under FDA review
- ➤Management will discuss commercial strategy and launch readiness
- ➤Praxis to participate in Guggenheim, UBS and Jefferies investor events
BOSTON, Oct. 27, 2026 (GLOBE NEWSWIRE) -- Praxis Precision Medicines, Inc. (NASDAQ: PRAX), a fully integrated, leading central nervous system (CNS) precision neuroscience biopharmaceutical company, today announced it will report financial results for the third quarter ended September 30, 2026, before the financial markets open on Monday, November 9, 2026. The Company also announced details of its upcoming Investor Day and participation in November investor conferences.
Praxis will host an Investor Day in New York on Thursday, November 12, 2026, at 8:00 a.m. ET. The event will be held in person and webcast live. To register, click here.
Get started
Create a free account to read the full story.